6.310USD-0.63%Mkt Cap: 328.54M USDP/E: —Last update: 2026-05-26
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Techn…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap328.54M USD
Enterprise Value446.86M USD
Revenue (TTM)87.82M USD
Gross Profit150.14M USD
Net Income (TTM)-193.88M USD
Revenue/Share1.694 USD
Last Price6.310 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees371
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS75901B1070
Valuation
P/E (Trailing)—
P/E (Forward)-2.68
PEG—
EV/EBITDA-1.85
EV/Revenue5.09
P/S3.97
P/B16.54
EPS (TTM)-5.60
EPS (Forward)-2.52
52W Range
5.4558% of range16.19
52W High16.19 USD
52W Low5.455 USD
Profitability
Gross Margin88.09%
Oper. Margin-1303.96%
EBITDA Margin-274.61%
Profit Margin-113.75%
ROE-188.72%
ROA-42.80%
Growth
Revenue Growth-92.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-123.96M USD
CapEx (TTM)2.41M USD
FCF Margin-158.25%
FCF Yield-42.30%
Net Debt97.90M USD
Net Debt/EBITDA-0.41
Balance Sheet
Debt/Equity0.72
Current Ratio2.62
Quick Ratio2.44
Book Value/Sh0.4080 USD
Cash/Share2.911 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)24.18 USD
Target Range10.00 USD – 50.00 USD
# Analysts11
Ownership
Shares Out.51.70M
Float43.08M
Insiders7.78%
Institutions84.75%
Short Interest
Short Ratio11.9d
Short % Float13.95%
Short % Out.12.97%
Shares Short6.69M
Short (prev mo.)6.71M
Technical
SMA 508.596 (-26.6%)
SMA 20010.51 (-40.0%)
Beta1.12
S&P 52W Chg28.31%
Avg Vol (30d)1.49M
Avg Vol (10d)3.01M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—